GO:0016263 N-acetylgalactosaminide beta-1,3-galactosyltransferase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0016263 defines the enzymatic activity that transfers galactose from UDP-galactose to an N-acetyl-alpha-D-galactosaminyl derivative, forming a beta-1,3 linkage and releasing UDP and H+.
• This activity is synonymous with Core 1 GalT and is responsible for the first committed step in Core 1 O-glycan biosynthesis.
• The reaction is essential for the structural maturation of mucin-type O-glycans on glycoproteins and influences downstream sialylation events.
• Altered expression of this activity can change cell-surface glycosylation patterns, which are frequently observed in cancer and other diseases.
• Researchers study this activity using glycosyltransferase assays, lectin binding, mass spectrometry, and CRISPR-based gene editing.
• Targeting this activity with CRISPR knockout, point mutation, or overexpression models enables causal dissection of O-glycan functions in health and disease.
Description
N-acetylgalactosaminide beta-1,3-galactosyltransferase activity (GO:0016263) is a molecular function that catalyzes the transfer of galactose from UDP-alpha-D-galactose to an N-acetyl-alpha-D-galactosaminyl (GalNAc) acceptor, forming a beta-D-galactosyl-(1->3)-N-acetyl-alpha-D-galactosaminyl derivative and releasing UDP and H+. This reaction is the defining step of Core 1 O-glycan synthesis, often referred to as Core 1 GalT activity, and it is critical for the elongation of mucin-type O-glycans on glycoproteins. The activity was first characterized in the context of brain O-glycan sialylation, where it regulates the expression of an alpha-N-acetylgalactosaminide alpha 2,6-sialyltransferase activity. Because O-glycans modulate protein stability, cell adhesion, and immune recognition, understanding this enzymatic activity is fundamental to glycobiology and disease research. Researchers rely on this GO term to annotate gene products that perform this specific galactosyltransferase reaction, enabling functional genomics and comparative studies across species.
N-acetylgalactosaminide beta-1,3-galactosyltransferase activity At A Glance
| GO ID | GO:0016263 |
|---|---|
| GO term | N-acetylgalactosaminide beta-1,3-galactosyltransferase activity |
| Ontology | molecular_function |
| Synonym | Core 1 GalT; glycoprotein-N-acetylgalactosamine 3-beta-galactosyltransferase activity; UDP-galactose:glycoprotein-N-acetyl-D-galactosamine 3-beta-D-galactosyltransferase activity; UDPgalactose:glycoprotein-N-acetyl-D-galactosamine 3-beta-D-galactosyltransferase activity; uridine diphosphogalactose-mucin beta-(1->3)-galactosyltransferase activity |
| Major function | Transfer of galactose from UDP-galactose to an N-acetyl-alpha-D-galactosaminyl derivative, forming a beta-1,3 linkage and releasing UDP and H+ |
| Reaction direction | Forward: an N-acetyl-alpha-D-galactosaminyl derivative + UDP-alpha-D-galactose = a beta-D-galactosyl-(1->3)-N-acetyl-alpha-D-galactosaminyl derivative + UDP + H+ |
| Substrates | N-acetyl-alpha-D-galactosaminyl derivative; UDP-alpha-D-galactose |
| Products | beta-D-galactosyl-(1->3)-N-acetyl-alpha-D-galactosaminyl derivative; UDP; H+ |
| Cofactors | Divalent metal ions (e.g., Mn2+) are commonly required by glycosyltransferases, though specific cofactor requirements for this activity are not detailed in the provided QuickGO data. |
What Is GO:0016263?
In simple terms, GO:0016263 describes an enzyme that attaches a galactose sugar to a specific sugar (GalNAc) already present on a protein, creating a beta-1,3 linkage. The official definition is: Catalysis of the reaction: an N-acetyl-alpha-D-galactosaminyl derivative + UDP-alpha-D-galactose = a beta-D-galactosyl-(1->3)-N-acetyl-alpha-D-galactosaminyl derivative + UDP + H+. This activity is also known as Core 1 GalT, glycoprotein-N-acetylgalactosamine 3-beta-galactosyltransferase, and UDP-galactose:glycoprotein-N-acetyl-D-galactosamine 3-beta-D-galactosyltransferase.
Why Is N-acetylgalactosaminide beta-1,3-galactosyltransferase activity Important in Cell Biology?
GO:0016263 is important because it represents the first committed step in the biosynthesis of Core 1 O-glycans, which are abundant on mucins and many cell-surface glycoproteins. This activity directly influences the subsequent addition of sialic acid and other sugars, thereby shaping the glycan landscape that governs cell-cell interactions, receptor signaling, and immune recognition. Dysregulation of this activity has been linked to altered glycosylation patterns in cancer and neurological conditions, making it a target for functional studies and therapeutic development.
• Defines the enzymatic activity that initiates Core 1 O-glycan elongation on glycoproteins.
• Regulates downstream sialylation events, including alpha 2,6-sialyltransferase activity in brain.
• Influences cell-surface glycosylation patterns that affect cell adhesion and signaling.
• Altered activity is associated with cancer-associated glycosylation changes.
• Plays a role in neurological processes through O-glycan sialylation in the brain.
• Provides a molecular target for CRISPR-based functional genomics.
• Enables annotation of genes encoding Core 1 GalT enzymes across species.
• Supports research into congenital disorders of glycosylation and other glycan-related diseases.
• Facilitates development of glycoengineered cell models for drug discovery.
• Helps explain how glycosylation affects protein stability and immune recognition.
Molecular Mechanism of N-acetylgalactosaminide beta-1,3-galactosyltransferase activity
Substrate recognition and binding
In simple terms: The enzyme first grabs the sugar (GalNAc) that is already attached to a protein and the donor sugar UDP-galactose.
The enzyme recognizes an N-acetyl-alpha-D-galactosaminyl derivative as the acceptor substrate and UDP-alpha-D-galactose as the donor substrate. This specificity ensures that galactose is added only to the correct acceptor, typically a GalNAc residue linked to serine or threonine on a glycoprotein.
Catalytic transfer and linkage formation
In simple terms: The enzyme then attaches galactose to the GalNAc sugar, creating a specific beta-1,3 bond.
Catalysis proceeds via transfer of galactose from UDP-alpha-D-galactose to the acceptor, forming a beta-D-galactosyl-(1->3)-N-acetyl-alpha-D-galactosaminyl derivative. This beta-1,3 linkage is the defining structural feature of Core 1 O-glycans.
Product release and reaction byproducts
In simple terms: After the bond is made, the enzyme releases the modified sugar, UDP, and a proton.
The reaction yields the elongated O-glycan product, UDP, and H+. The release of UDP and H+ is part of the catalytic cycle and helps drive the reaction forward under physiological conditions.
Role in O-glycan sialylation regulation
In simple terms: The product made by this enzyme can be further modified by sialic acid, and this step controls that later modification.
In brain tissue, the beta-1,3-galactosyltransferase activity regulates the expression of an alpha-N-acetylgalactosaminide alpha 2,6-sialyltransferase activity, thereby influencing the sialylation state of O-glycans. This regulatory link highlights how GO:0016263 activity can indirectly control downstream glycosylation events.
Key Genes Involved in GO:0016263 N-acetylgalactosaminide beta-1,3-galactosyltransferase activity
The following genes and proteins are associated with or relevant to N-acetylgalactosaminide beta-1,3-galactosyltransferase activity (GO:0016263) based on published literature and functional annotations.
| Gene | Major Role | Research Relevance |
|---|---|---|
| C1GALT1 | Encodes the core 1 beta-1,3-galactosyltransferase enzyme that catalyzes the defining reaction of GO:0016263 | Central to Core 1 O-glycan biosynthesis; knockout models show loss of Core 1 structures |
| C1GALT1C1 | Encodes a chaperone (Cosmc) required for C1GALT1 activity | Mutations cause Tn syndrome and affect GO:0016263 activity |
| GALNT1 | Initiates O-glycosylation by adding GalNAc to serine/threonine | Provides the acceptor substrate for GO:0016263 |
| GALNT2 | Adds GalNAc to specific protein substrates | Upstream of GO:0016263 in O-glycan pathways |
| GALNT3 | Initiates O-glycosylation on FGF23 | Affects phosphate homeostasis; related to O-glycan biology |
| GALNT4 | Initiates O-glycosylation in various tissues | Contributes to acceptor supply for GO:0016263 |
| GALNT5 | Initiates O-glycosylation in gastrointestinal tract | Relevant to mucin-type O-glycan synthesis |
| GALNT6 | Initiates O-glycosylation in mammary tissue | Linked to cancer-associated glycosylation |
| GALNT7 | Initiates O-glycosylation in multiple tissues | Provides substrates for Core 1 extension |
| GALNT10 | Initiates O-glycosylation on specific proteins | Affects O-glycan diversity |
| ST3GAL1 | Adds sialic acid to Core 1 O-glycans | Downstream of GO:0016263; competes with other modifications |
| ST6GALNAC1 | Adds sialic acid to GalNAc residues | Regulated by GO:0016263 activity in brain |
| ST6GALNAC2 | Adds sialic acid to GalNAc residues | Affects O-glycan sialylation patterns |
| B3GALT1 | Beta-1,3-galactosyltransferase family member | May share substrate specificity with GO:0016263 |
| B3GALT2 | Beta-1,3-galactosyltransferase family member | Related to galactose transfer reactions |
| B3GALT4 | Beta-1,3-galactosyltransferase family member | Involved in glycolipid and glycoprotein synthesis |
| B3GALT5 | Beta-1,3-galactosyltransferase family member | Contributes to glycan diversity |
| B4GALT1 | Beta-1,4-galactosyltransferase | Distinct linkage but related to galactosylation pathways |
How Is N-acetylgalactosaminide beta-1,3-galactosyltransferase activity Regulated?
The activity of N-acetylgalactosaminide beta-1,3-galactosyltransferase (GO:0016263) is regulated at multiple levels. In brain, the beta-1,3-galactosyltransferase activity controls the expression of an alpha-N-acetylgalactosaminide alpha 2,6-sialyltransferase activity, indicating a regulatory relationship between Core 1 synthesis and subsequent sialylation. Additionally, the enzyme requires a specific chaperone, Cosmc (C1GALT1C1), for proper folding and activity, and loss of Cosmc leads to inactivation of the enzyme. Substrate availability, including UDP-galactose levels and the presence of appropriate GalNAc acceptors, also influences the reaction rate. Post-translational modifications and cellular localization may further modulate activity, though specific mechanisms are not detailed in the provided literature.
N-acetylgalactosaminide beta-1,3-galactosyltransferase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| C1GALT1 | Cancer, Tn syndrome, congenital disorders of glycosylation | Knockout cell lines (e.g., HEK293, HeLa) to assess Core 1 loss |
| C1GALT1C1 | Tn syndrome, autoimmune disorders | Point mutation knock-in to mimic patient mutations |
| ST6GALNAC1 | Neurological disorders, cancer | Overexpression in neuronal cell lines to study sialylation |
| GALNT1 | Cancer, developmental disorders | Knockout models to reduce acceptor substrate for GO:0016263 |
| ST3GAL1 | Cancer, immune disorders | Knock-in of tagged enzyme to track O-glycan sialylation |
Cancer-associated glycosylation changes
Alterations in O-glycan biosynthesis, including changes in Core 1 GalT activity (GO:0016263), are frequently observed in cancer. Loss of Core 1 structures can expose Tn antigen, a tumor-associated carbohydrate antigen, leading to altered cell adhesion and immune recognition. Understanding how GO:0016263 activity is dysregulated in cancer may inform diagnostic and therapeutic strategies.
Neurological disorders and brain glycosylation
In the brain, O-glycan sialylation is regulated by the beta-1,3-galactosyltransferase activity (GO:0016263), which controls an alpha 2,6-sialyltransferase activity. Disruption of this regulatory axis may contribute to neurological conditions characterized by abnormal glycosylation, although specific disease links require further investigation.
Congenital disorders of glycosylation
Defects in O-glycan biosynthesis, including mutations in C1GALT1 or its chaperone C1GALT1C1, can cause congenital disorders of glycosylation with multisystem symptoms. These conditions highlight the importance of GO:0016263 activity for normal development and physiology.
From N-acetylgalactosaminide beta-1,3-galactosyltransferase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of GO:0016263 activity alter cell-surface glycosylation? | CRISPR knockout of C1GALT1 in HEK293 or HeLa cells |
| How do patient mutations affect enzyme function? | Point mutation knock-in of C1GALT1 or C1GALT1C1 in isogenic cell lines |
| Can a tagged enzyme be used to track localization? | Knock-in of fluorescent or epitope-tagged C1GALT1 |
| Does overexpression of GO:0016263 change O-glycan profiles? | Overexpression of C1GALT1 in cancer cell lines |
| What are the downstream effects on sialylation? | Knockout of C1GALT1 followed by lectin blotting and mass spectrometry |
| Can we screen for regulators of GO:0016263? | CRISPR library screening in cells with a glycosylation reporter |
How to Study the N-acetylgalactosaminide beta-1,3-galactosyltransferase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Glycosyltransferase assay | Enzymatic transfer of galactose to GalNAc acceptor | Confirming GO:0016263 activity in cell lysates |
| Lectin blotting (PNA) | Presence of Core 1 O-glycans | Assessing loss of GO:0016263 activity in knockout cells |
| Mass spectrometry | O-glycan structures and linkage positions | Detailed glycan profiling of wild-type vs. mutant |
| Flow cytometry with lectins | Cell-surface O-glycan expression | High-throughput screening of glycosylation changes |
| CRISPR knockout | Loss of gene function | Studying C1GALT1 or C1GALT1C1 in isogenic cell lines |
| CRISPR point mutation | Specific amino acid changes | Modeling patient mutations in C1GALT1 |
| CRISPR knock-in | Tagged or reporter gene | Tracking enzyme localization and dynamics |
| Overexpression | Increased enzyme levels | Gain-of-function studies in cancer cells |
Glycosyltransferase activity assays
Enzymatic activity of GO:0016263 can be measured using radioactive or fluorescent donor substrates (UDP-galactose) and acceptor substrates (GalNAc derivatives), followed by product separation and quantification. These assays are essential for confirming enzyme function and kinetics.
Lectin-based detection of O-glycans
Lectin blotting with peanut agglutinin (PNA) or other lectins can detect Core 1 O-glycans on glycoproteins, providing a semi-quantitative readout of GO:0016263 activity in cells and tissues. Loss of Core 1 structures results in reduced lectin binding.
Mass spectrometry for glycan profiling
Mass spectrometry-based glycomics and glycoproteomics can precisely characterize O-glycan structures, including the beta-1,3-galactose linkage formed by GO:0016263. This method is powerful for comparing wild-type and mutant cells.
CRISPR-based functional genomics
CRISPR knockout, point mutation, and knock-in models enable causal interrogation of genes encoding GO:0016263 activity, such as C1GALT1 and C1GALT1C1. These models can be combined with RNA-seq, proteomics, and imaging to dissect downstream effects.
How CRISPR Can Be Used to Study GO:0016263 N-acetylgalactosaminide beta-1,3-galactosyltransferase activity
Knockout
CRISPR knockout of C1GALT1 or C1GALT1C1 eliminates GO:0016263 activity, leading to loss of Core 1 O-glycans and accumulation of Tn antigen. These models are invaluable for studying the consequences of O-glycan truncation in cancer and immune cells.
Point Mutation
Point mutation knock-in can recreate patient-specific missense mutations in C1GALT1 or C1GALT1C1, allowing researchers to assess how these mutations affect enzyme stability, activity, and substrate binding. Such models help establish genotype-phenotype relationships.
Knock-in
Knock-in of epitope tags or fluorescent proteins into the endogenous C1GALT1 locus enables real-time tracking of enzyme localization and dynamics without altering expression levels. This approach is useful for studying trafficking and interaction partners.
Overexpression
Overexpression of C1GALT1 or other genes encoding GO:0016263 activity can increase Core 1 O-glycan levels, potentially altering cell adhesion, signaling, and tumorigenicity. Overexpression models are used to test gain-of-function effects in cancer and developmental biology.
How EDITGENE Supports N-acetylgalactosaminide beta-1,3-galactosyltransferase activity Research
Researchers studying N-acetylgalactosaminide beta-1,3-galactosyltransferase activity-related genes often need to determine whether a candidate gene is causally involved in O-glycan biosynthesis, disease progression, or cellular signaling. EDITGENE provides a comprehensive suite of CRISPR-based services to generate precisely engineered cell models that answer these questions.
Contact EDITGENE today to design your custom CRISPR model for N-acetylgalactosaminide beta-1,3-galactosyltransferase activity research.
Frequently Asked Questions About N-acetylgalactosaminide beta-1,3-galactosyltransferase activity
What is N-acetylgalactosaminide beta-1,3-galactosyltransferase activity?
It is a molecular function (GO:0016263) that catalyzes the transfer of galactose from UDP-galactose to an N-acetyl-alpha-D-galactosaminyl derivative, forming a beta-1,3 linkage and releasing UDP and H+.
What genes are involved in N-acetylgalactosaminide beta-1,3-galactosyltransferase activity?
The primary gene is C1GALT1, which encodes the core 1 beta-1,3-galactosyltransferase enzyme; its chaperone C1GALT1C1 is also essential for activity.
What is the reaction catalyzed by GO:0016263?
The reaction is: an N-acetyl-alpha-D-galactosaminyl derivative + UDP-alpha-D-galactose = a beta-D-galactosyl-(1->3)-N-acetyl-alpha-D-galactosaminyl derivative + UDP + H+.
What are the synonyms for GO:0016263?
Synonyms include Core 1 GalT, glycoprotein-N-acetylgalactosamine 3-beta-galactosyltransferase activity, and UDP-galactose:glycoprotein-N-acetyl-D-galactosamine 3-beta-D-galactosyltransferase activity.
How is N-acetylgalactosaminide beta-1,3-galactosyltransferase activity regulated?
It is regulated by substrate availability, the chaperone Cosmc (C1GALT1C1), and in brain, it controls an alpha 2,6-sialyltransferase activity.
What diseases are associated with altered GO:0016263 activity?
Altered activity is linked to cancer-associated glycosylation changes, Tn syndrome, and congenital disorders of glycosylation.
How can I study N-acetylgalactosaminide beta-1,3-galactosyltransferase activity in the lab?
Common methods include glycosyltransferase assays, lectin blotting, mass spectrometry, and CRISPR-based gene editing of C1GALT1 or C1GALT1C1.
What is Core 1 GalT?
Core 1 GalT is a synonym for N-acetylgalactosaminide beta-1,3-galactosyltransferase activity (GO:0016263), the enzyme that synthesizes Core 1 O-glycans.
Can CRISPR be used to knockout C1GALT1?
Yes, CRISPR knockout of C1GALT1 is a standard approach to eliminate GO:0016263 activity and study the resulting loss of Core 1 O-glycans.
What cell models are suitable for studying GO:0016263?
HEK293, HeLa, and other mammalian cell lines are commonly used; EDITGENE provides custom knockout, knock-in, and overexpression models for these studies.
Conclusion
N-acetylgalactosaminide beta-1,3-galactosyltransferase activity (GO:0016263) is a fundamental enzymatic function in O-glycan biosynthesis, responsible for the first committed step of Core 1 formation. Its regulation impacts downstream sialylation, cell-surface glycosylation, and disease-associated phenotypes. By leveraging CRISPR-based models and advanced analytical methods, researchers can dissect the precise roles of this activity in health and disease, paving the way for novel therapeutic strategies.
References
- 1. Baubichon-Cortay H et al.. 1989. Evidence for an O-glycan sialylation system in brain. Characterization of a beta-galactoside alpha 2,3-sialyltransferase from rat brain regulating the expression of an alpha-N-acetylgalactosaminide alpha 2,6-sialyltransferase activity.. Eur J Biochem 182(2):257-65 PMID: 2472271
